The impact of antiretroviral therapy on symptom burden among HIV outpatients with low CD4 count in rural Uganda: nested longitudinal cohort study
Open Access
- 13 July 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Palliative Care
- Vol. 17 (1), 1-9
- https://doi.org/10.1186/s12904-017-0215-y
Abstract
Individuals with HIV have a high prevalence of physical and psychological symptoms throughout their disease course. Despite the clinical and public health implications of unresolved pain and symptoms, little is known about the effect of anti-retroviral therapy (ART) on these outcomes. This study aimed to assess the impact on symptom burden for the year after ART initiation in individuals with a CD4 count <200 cells/uL in Uganda. HIV-infected, ART-naıve adults referred from voluntary testing and counseling services in rural Uganda for enrollment into a randomized controlled trial to test fluconazole as primary prophylaxis against cryptococcal disease were invited to complete the Memorial Symptom Assessment Scale-Short Form (MSAS-SF) prior to commencing ART and at two subsequent follow up visits. This tool measures self-reported 7-day period prevalence and associated burden of physical and psychological symptoms. Changes in the total number of symptoms and distress indices with time on ART and trial arm were investigated through fitting Linear Mixed Models for repeated measures. During the first year of ART initiation the prevalence of most individual symptoms remained constant. The notable exceptions which improved after commencing ART are as follow; prevalence of pain (prevalence changed from 79% to 60%), weight loss (67% to 31%), lack of appetite (46% to 28%), feeling sad (52% to 25%) and difficulty sleeping (35% to 23%). The total number of symptoms and distress indices reduced after treatment commenced. Of concern was that half or more study participants remained with symptoms of pain (60%), itching (57%), skin changes (53%) and numbness in hands and feet (52%) after starting ART. Sixteen symptoms remained with a burden of 25% or more. Despite the beneficial effect of ART on reducing symptoms, some patients continue to experience a high symptom burden. It is essential that HIV services in sub-Saharan Africa integrate management of symptoms into their programmes. CRYPTOPRO [ISRCTN 76481529 ], November 2004.Funding Information
- Medical Research Council
This publication has 34 references indexed in Scilit:
- Quality of life and wellbeing among HIV outpatients in East Africa: a multicentre observational study.BMC Infectious Diseases, 2014
- Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trialThe Lancet Infectious Diseases, 2011
- Behavioral Surveillance Study: Sexual Risk Taking Behaviour in UK HIV Outpatient AttendeesAIDS and Behavior, 2011
- Physical and Psychological Symptoms and Risk of Virologic Rebound Among Patients With Virologic Suppression on Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Translational methods in biostatistics: linear mixed effect regression models of alcohol consumption and HIV disease progression over timeEpidemiologic Perspectives & Innovations, 2007
- Adverse quality of life consequences of antiretroviral medicationsAIDS Care, 2007
- An investigation into the health-related quality of life of individuals living with HIV who are receiving HAARTAIDS Care, 2005
- Does palliative care improve outcomes for patients with HIV/AIDS? A systematic review of the evidenceSexually Transmitted Infections, 2005
- Long-Term Quality-of-Life Outcomes Among Adults Living with HIV in the HAART Era: The Interplay of Changes in Clinical Factors and Symptom ProfileAIDS and Behavior, 2004
- The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART.AIDS and Behavior, 2003